GENinCode Plc

Equities

GENI

GB00BL97B504

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. Other stock markets 16:35:26 17/05/2024 BST			5-day change	1st Jan Change
8.75 ^GBX	0.00%		-5.41%	+66.67%

04-04	GENinCode Plc Announces Publication by the American Journal of Preventive Cardiology of A Study on 'Polygenic Risk and Incident Heart Disease in a Large Multiethnic Cohort	CI
03-21	GENinCode says ROCA recommended as ovarian cancer risk test in England	AN

GENinCode Plc Reports Earnings Results for the Full Year Ended December 31, 2022

June 06, 2023 at 07:00 am

GENinCode Plc reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was GBP 1.43 million compared to GBP 1.15 million a year ago. Net loss was GBP 5.56 million compared to GBP 4.14 million a year ago.

Latest news about GENinCode Plc

GENinCode Plc Announces Publication by the American Journal of Preventive Cardiology of A Study on 'Polygenic Risk and Incident Heart Disease in a Large Multiethnic Cohort	04-04	CI
GENinCode says ROCA recommended as ovarian cancer risk test in England	03-21	AN
GENinCode gets GBP57,000 in retail offer, well below maximum	12-28	AN
GENinCode Raises GBP4 Million from Share Sale	12-28	MT
GENinCode raises GBP4 million via placing and subscription	12-21	AN
Genincode Plc Announces Placing And Subscription To Raise A Minimum Of £4.0 Mln	12-21	RE
Aura eyes Tiris expansion; Kavango backs Pambili	11-29	AN
GENinCode plc Agrees with the Food and Drug Administration to Create New Regulatory Class for Polygenic Risk scores and Transition Its Premarket Notification 510(K) Submission to A De Novo Pathway	11-29	CI
EARNINGS: ASA interim profit plummets; Mycelx loss narrows, revenue up	20/09/23	AN
Earnings Flash (GENI.L) GENINCODE Reports H1 Revenue GBP950,000	20/09/23	MT
Earnings Flash (GENI.L) GENINCODE Posts H1 Loss GBX-3.33	20/09/23	MT
GENinCode Plc Provides Revenue Guidance for the Second Half of 2023	20/09/23	CI
GENinCode Plc Reports Earnings Results for the Half Year Ended June 30, 2023	20/09/23	CI
Genincode plc Announces CARDIO inCode study on risk of incident Coronary Heart Disease	30/08/23	CI
GENinCode Shares Rise on FDA Filing for Heart Disease Test Kit	16/08/23	DJ
GENinCode Submits Premarket Notification for US Commercial Distribution of Polygenic Test Kit	16/08/23	MT
GENinCode plc Files its Premarket Notification with the Food and Drug Administration to Expand Its US Commercial Distribution of the Cardio InCode-Score Polygenic Test for the Risk Assessment and Prevention of Coronary Heart Disease	16/08/23	CI
Certain Ordinary Shares of GENinCode Plc are subject to a Lock-Up Agreement Ending on 23-JUL-2023.	22/07/23	CI
GENinCode Shares Rise Amid US Partnership with MedStar Health	19/07/23	MT
GENinCode and MedStar collaborate on coronary heart disease testing	19/07/23	AN
GENinCode Plc Announces Collaboration with MedStar Health	19/07/23	CI
GENinCode annual loss widens; focuses on US, EU, and NHS in UK	06/06/23	AN
GENinCode Plc Reports Earnings Results for the Full Year Ended December 31, 2022	06/06/23	CI
GENinCode Plc Reports Earnings Results for the Full Year Ended December 31, 2022	06/06/23	CI
GENinCode Plc Auditor Raises 'Going Concern' Doubt	04/06/23	CI

Chart GENinCode Plc

Duration

Period

More charts

Company Profile

GENinCode Plc is a United Kingdom-based polygenics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease. The Company's core products include Cardio inCode - Score and Check - Coronary predictive/risk assessment; Thrombo inCode - Hematology, Recurrent Pregnancy Loss and Oncology, Thrombosis (blood clots) predictive/risk assessment; Lipid inCode - Familial Hypercholesterolemia Diagnosis and risk stratification, and SudD inCode - Hereditary Cardiomiopathies diagnosis, Risk assessment for sudden cardiac events.

Sector

Medical Equipment, Supplies & Distribution

Calendar

11/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for GENinCode Plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
GENINCODE PLC	+66.67%	19.62M
BIOMÉRIEUX	-4.67%	12.33B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-5.19%	8.14B
LANTHEUS HOLDINGS, INC.	+28.50%	5.62B
AUTOBIO DIAGNOSTICS CO., LTD.	-8.09%	4.24B
10X GENOMICS, INC.	-55.31%	3.06B
ANDON HEALTH CO., LTD.	+13.49%	2.76B
VITROLIFE AB	-1.34%	2.41B
MYRIAD GENETICS, INC.	+32.24%	2.23B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-3.55%	1.87B

Diagnostic & Testing Substances